Overview

A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients (Study E2080-J081-304)

Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
To confirm that the combination therapy of rufinamide has superior efficacy compared to placebo in patients with Lennox-Gastaut syndrome.
Phase:
Phase 3
Details
Lead Sponsor:
Eisai Limited
Treatments:
Rufinamide